ARWR Reiterated by HC Wainwright & Co. -- Price Target Maintaine

Arrowhead Pharmaceuticals (ARWR) reported Phase 3 trial results for plozasiran, showing 79-81% triglyceride reductions vs. 27% for placebo. Pooled analysis indicated a 78% reduction in pancreatitis events, but absolute risk reduction was 4.1%. ARWR plans to submit a broader-label application by 2026. Plozasiran is FDA-approved for familial chylomicronemia syndrome. The company aims to expand its use to severe hypertriglyceridemia. Triglyceride reductions were consistent, with 91-93% of treated p

Plozasiran, an FDA-approved drug by Arrowhead, reduced triglycerides by up to 81% in severe hypertriglyceridemia patients and prevented pancreatitis. Two trials, SHASTA-3 and SHASTA-4, showed sustained reductions and favorable safety profiles. Gerald F. Watts, a cardiometabolic medicine professor, highlighted the therapy's potential impact on clinical practice. The drug is not yet approved for severe hypertriglyceridemia.

Arrowhead Pharmaceuticals presented late-stage trial results for plozasiran (Redemplo) in severe hypertriglyceridemia, showing favorable safety and efficacy. Analysts are divided: Stifel highlights its safety and dosing advantages over Ionis' Tryngolza, while BMO favors Tryngolza due to glycemic control concerns. Arrowhead plans an FDA submission for expanded use later this year.

Arrowhead Pharmaceuticals presented Phase 3 data showing plozasiran reduced triglycerides by 79-81% and acute pancreatitis events by 78% in severe hypertriglyceridemia patients. Over 90% of patients achieved TG levels below 500 mg/dL. The company plans to file an FDA application by year-end 2026, utilizing a Priority Review Voucher. Plozasiran demonstrated a favorable safety profile.

Arrowhead Pharmaceuticals (NASDAQ: ARWR) said the European Commission approved REDEMPLO (plozasiran) in June 2026, and it is now listed in Germany’s Lauer-Taxe database for prescribing and reimbursement. REDEMPLO is used with diet for adult FCS patients, with dosing as a subcutaneous injection every three months. Phase 3 PALISADE showed significant fasting triglyceride reductions at Month 10 versus placebo; common adverse reactions included hyperglycaemia and headache.

Arrowhead Pharmaceuticals (ARWR) reported Q3 2026 results. Sales rose to $75.25 million from $27.77 million a year earlier, but net loss widened to $194.28 million and loss per share increased to $1.36 from $1.26. For the first nine months of 2026, it swung to a $296.21 million net loss despite $400+ million in sales, citing higher expenses and lower collaboration revenue.